

1 **Plasma Metallomics Reveals Potential Biomarkers and Insights into the Ambivalent**  
2 **Associations of Elements with Acute Myocardial Infarction**

3 Si Ying Lim<sup>1,2</sup>, Hiranya Dayal<sup>2</sup>, Song Jie Seah<sup>2</sup>, Regina Pei Woon Tan<sup>2</sup>, Zhi En Low<sup>2</sup>, Anna  
4 Karen Carrasco Laserna<sup>2,3</sup>, Sock Hwee Tan<sup>4</sup>, Mark Y. Chan<sup>4</sup>, and Sam Fong Yau Li<sup>1,2,\*</sup>

5 <sup>1</sup> NUS Graduate School's Integrative Sciences & Engineering Programme (ISEP), National  
6 University of Singapore, University Hall, Tan Chin Tuan Wing, Singapore 119077

7 <sup>2</sup> Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore  
8 117543

9 <sup>3</sup> Central Instrument Facility, Office of the Vice Chancellor for Research and Innovation, De  
10 La Salle University, 2401 Taft Avenue, Malate, Manila, Philippines 1004

11 <sup>4</sup> Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University  
12 of Singapore, Singapore 117599

13 \* Correspondence: Fax +65-6779-1691 Tel: +65-6516-2681; E-mail [chmlifys@nus.edu.sg](mailto:chmlifys@nus.edu.sg)

## 1 **Abstract**

2 Acute myocardial infarction (AMI) is a leading cause of mortality and morbidity worldwide.  
3 Using a validated and efficient ICP-MS/MS-based workflow, a total of 30 metallomic features  
4 were profiled in a study comprising 101 AMI patients and 66 age-matched healthy controls.  
5 The metallomic features include 12 essential elements (Ca, Co, Cu, Fe, K, Mg, Mn, Na, P, S,  
6 Se, Zn), 8 non-essential/toxic elements (Al, As, Ba, Cd, Cr, Ni, Rb, Sr, U, V), and 10 clinically  
7 relevant element-pair product/ratios (Ca/Mg, Ca×P, Cu/Se, Cu/Zn, Fe/Cu, P/Mg, Na/K, Zn/Se).  
8 Preliminary linear regression with feature selection confirmed smoking status as a predominant  
9 determinant for the non-essential/toxic elements, and revealed potential routes of action.  
10 Univariate assessments with adjustments for covariates revealed insights into the ambivalent  
11 relationships of Cu, Fe, and P with AMI, while also confirming cardioprotective associations  
12 of Se. Also, beyond their roles as risk factors, Cu and Se may be involved in the response  
13 mechanism in AMI onset/intervention, as demonstrated via longitudinal data analysis with 2  
14 additional time-points (1-/6-month follow-up). Finally, based on both univariate tests and  
15 multivariate classification modelling, potentially more sensitive markers measured as element-  
16 pair ratios were identified (e.g., Cu/Se, Fe/Cu). Overall, metallomics-based biomarkers may  
17 have utility for AMI prediction.

## 18 **Keywords**

19 Metallomics, Ionomics, Acute Myocardial Infarction, Coronary Heart Disease, Cardiovascular  
20 Disease, Copper, Selenium, Biomarker, ICP-MS

## 1 **1. Introduction**

2 Acute myocardial infarction (AMI), a condition classified under coronary heart disease  
3 (CHD), is one of the leading causes of mortality and morbidity worldwide despite remarkable  
4 progress in disease diagnosis and treatment.<sup>1, 2</sup> Both clinical and epidemiological studies have  
5 demonstrated the cardioprotective and detrimental associations of essential minerals and non-  
6 essential/toxic metal exposure respectively, with risks of AMI, CHD, or cardiovascular disease  
7 (CVD) in general.<sup>3, 4</sup> However, given the global-acting and non-independent nature of these  
8 various metals in health and disease, their values as biomarkers are limited. Moreover, the  
9 benefits of public health efforts and intervention strategies (*e.g.*, via dietary supplementation  
10 or reducing anthropogenic exposure) remain unclarified.<sup>3, 4</sup> Thus, more accurate and in-depth  
11 characterisation of the associations between these different types of elements with AMI  
12 aetiology is vital.

13 Thus, omics strategies such as metallomics have great merit, as the interplay between  
14 various non-independent elements and other biomolecules may be revealed. However, as  
15 shown in a recent bibliometric analysis on omics applications in CHD research, comprehensive  
16 metallomics analysis has seldom been done in this area, and there was only 1 study on blood  
17 plasma metallomics study in a subgroup of AMI patients.<sup>5</sup> This could be because metals have  
18 rarely been conjugated with the omics world unlike the other omics frontrunners, and that  
19 metallomics only garnered greater attention recently.<sup>5, 6</sup> Nevertheless, metallomics has already  
20 been widely applied in environmental studies and toxicological appraisals, and methods have  
21 been rapidly developed to enable quick and efficient metallomic profiling.<sup>7</sup> This study's  
22 overarching goal is therefore to capitalise on such developments for bridging existing research  
23 gaps regarding the AMI metallome.

24 With that overarching goal, our study aims to assess both essential elements and non-  
25 essential/toxic elements with as wide a coverage as possible. To achieve that, the inductively

1 coupled plasma – mass spectrometry (ICP-MS) with MS/MS and collision/reaction cell (CRC)  
2 capabilities was used for its remarkable sensitivity, enabling the analysis of more elements at  
3 trace and ultra-trace levels.<sup>8</sup> Also, beyond solely comparing elemental concentrations in the  
4 blood plasma, element ratios are also relevant. This is because the dynamic balance or  
5 metabolic crossroads of multiple elements have implications on various biological processes  
6 in human health and disease, and could also potentially link health/disease with diet and  
7 environmental changes.<sup>9</sup> Thus, we identified a few element-pairs relevant to CVD and in  
8 human health in general: Ca/Mg<sup>10, 11</sup>, Ca×P<sup>12-14</sup>, Cu/Se<sup>15</sup>, Cu/Zn<sup>16, 17</sup>, Fe/Cu<sup>18</sup>, Na/K<sup>19, 20</sup>,  
9 P/Mg<sup>21</sup>, and Zn/Se<sup>15</sup>. Our work thereby includes these additional variables as part of the  
10 metallomics profile, to paint a more comprehensive picture about these elements in AMI.

11 In summary, because few studies have examined the association between circulating  
12 element (both essential and non-essential/toxic) levels and AMI, and none so far has also  
13 comprehensively assessed several element product/ratios in Asian populations across 3 time-  
14 points, our study presents useful insights into the pertinent disturbances in AMI metallome.

## 15 **2. Materials and methods**

### 16 *2.1. Reagents and chemicals*

17 All chemicals used were of trace analysis grade (99.999%) unless otherwise stated, and  
18 ultrapure water was also used for all chemical and sample preparation. The multi-element  
19 standard (IV-ICPMS-71A) was purchased from Inorganic Ventures (Christiansburg, VA,  
20 USA), and it contains the following elements in 3% nitric acid: Ag, Al, As, B, Ba, Be, Ca, Cd,  
21 Ce, Co, Cr, Cs, Cu, Dy, Er, Eu, Fe, Ga, Gd, Ho, K, La, Lu, Mg, Mn, Na, Nd, Ni, P, Pb, Pr, Rb,  
22 S, Se, Sm, Sr, Th, Ti, Tm, U, V, Yb, Zn. The ICPMS internal standard mix was purchased from  
23 Agilent Technologies (Santa Clara, CA, USA, and it contains Bi, Ge, In, Li-6, Rh, Sc and Tb.  
24 The 60% nitric acid (ultrapure; any metals at sub ppt levels) used for all experiments was  
25 purchased from Kanto Chemical Co. (Tokyo, Japan).

## 1 2.2. *Patients and controls*

2 This study was approved by the National Healthcare Group Domain Specific Review Board  
3 (NHG DSRB; REF NO. 2013-00248 and 2016-00210), and all subjects gave their informed  
4 consent to participate prior to the inclusion. All experiments were performed in compliance  
5 with the relevant laws and institutional guidelines. Blood plasma samples from 101 AMI  
6 patients were collected from the National University Heart Centre, Tan Tock Seng Hospital,  
7 Changi General Hospital, Sarawak General Hospital Heart Centre, and Christchurch District  
8 Hospital. AMI plasma samples were collected 24-48 hours post-percutaneous coronary  
9 intervention (PCI). Samples from two additional follow-up time-points were also collected  
10 from the AMI patients (T1: 24 – 48 hours post-PCI; T2: 1 month after T1; T3: 6 months after  
11 T1). Blood plasma samples from 66 matched healthy community-dwelling controls were  
12 collected from Singapore. All blood samples were immediately centrifuged at – 4 °C and were  
13 stored at – 80 °C prior to analysis.

## 14 2.3. *Metallomics sample preparation*

15 To obtain elemental samples from human blood plasma, acid digestion aided with heating  
16 via a hotplate was done. Specifically, 80 µL blood plasma was added into a 15 mL  
17 polypropylene centrifuge tube, followed by the addition of 80 µL ultrapure water and 80 µL  
18 ultrapure nitric acid. The centrifuge tubes were gently swirled to allow mixing. Immediately  
19 after, the samples were heated using a hotplate at 98 °C for 2 hours. To further process the  
20 samples for ICP-MS analysis, the digested samples were diluted to 8 mL with ultrapure water.  
21 The diluted samples were then filtered using 2.2 µm PTFE syringe filters into clean centrifuge  
22 tubes. Blank samples were prepared in the same way, but with the blood plasma component  
23 replaced with ultrapure water. The samples were then stored at 4 °C until ICP-MS analysis as  
24 recommended by a recent report.<sup>22</sup>

## 25 2.4. *ICP-MS analysis*

1 ICP-MS analysis was done using the 8900 ICP-MS/MS system (equipped with triple  
2 quadruple mass spectrometer) from Agilent Technologies. To optimise sensitivity and  
3 accuracy, various CRC modes using the tandem mass spectrometer were used to quantitate  
4 different elements. Supplementary Table S1 summarises the instrument and CRC parameters.  
5 To correct for matrix effects and non-spectral interferences, multiple elements from the internal  
6 standard mix were spiked online and elemental concentrations were normalised to the internal  
7 standards. To obtain optimal precision and accuracy, the internal standard analyte for each  
8 element was selected as close in mass number as possible to that of the analyte element, with  
9 ionisation energies considered as well. The masses and mass shifts used for integration for each  
10 element and the corresponding internal standard analytes are included in Supplementary Table  
11 S2. To obtain elemental concentrations of the samples, external standard calibration was done  
12 using the multi-element standard prepared in various concentrations. It was noted that a few  
13 elements (Al, Ca, K, Mg, Na, P, S) were present in higher abundance where their concentrations  
14 in some or all of the plasma samples exceeds the external standard calibration range. To  
15 determine their concentrations, the samples were diluted (dilution factor = 50) and re-analysed  
16 by the ICP-MS.

### 17 *2.5. Data processing and statistical analysis*

18 All statistical analyses were conducted in *R* (R Core Team).<sup>23</sup> Normality of all metabolite  
19 and glycan features was first assessed via the Kolmorov-Smirnov test. Since non-normal  
20 distributions ( $p < 0.05$  based on Kolmorov-Smirnov test) were found with some of the features,  
21 non-parametric tests were done subsequently. Baseline characteristics among patients and  
22 controls were compared using Mann Whitney test for continuous variables, and Fisher's Exact  
23 test for categorical variables. Differences in plasma levels of the metallomic features between  
24 patient groups were also assessed using the Mann Whitney test. Linear regression modelling  
25 for identifying independent determinants of the metallomic features amongst covariables was

1 done with backwards elimination to remove non-significant variables until all variables  
2 remaining in the model had  $p$ -value  $< 0.05$ . Analysis of covariance (ANCOVA) with the  
3 inclusion of significant determinants as covariates was done by implementing a generalised  
4 linear model (GLM) with Bonferroni correction for multiple comparisons. Analysis of the  
5 longitudinal data with 3 time-points was achieved via Friedman test, and Kendall's  $W$   
6 coefficient of concordance was evaluated as the effect size for Friedman test.

7 Classification modelling was done on MetaboAnalyst (<http://www.metaboanalyst.ca>). To  
8 prepare the dataset with both clinical and metallomics variables for multivariate analysis, log-  
9 transformation and scaling via mean-centring was done. The receiving operating characteristic  
10 (ROC) curve for biomarker identification and performance evaluation was generated based on  
11 random forest classification modelling with repeated random sub-sampling cross-validation  
12 (30 iterations; each iteration uses 2/3 samples for feature selection and model training, and  
13 remaining 1/3 for testing). Important features were identified and ranked based on decreases in  
14 accuracy.

### 15 **3. Results and discussion**

#### 16 *3.1. Generation of plasma metallomic profiles*

17 Out of 43 elements from the multi-element standard, 22 were successfully quantified from  
18 the human blood plasma samples via ICP-MS analysis as described. To validate that the sample  
19 preparation workflow involving nitric acid digestion with hotplate-assisted heating was  
20 sufficient to digest and stabilise the 22 detected elements, and that the CRC modes and internal  
21 standard elements were appropriate, method repeatability and recovery were assessed.

22 For assessing intra-day repeatability/precision, three independent digestions of the same  
23 pooled plasma sample spiked with multi-element standard (final concentration of each element  
24 = 500 ppb) were done and analysed. Additional tests with dilution (dilution factor = 50) were

1 also done for evaluating some of the elements present at lower amounts in blood plasma. For  
2 assessing inter-day repeatability or intermediate precision, nine independent extractions from  
3 the same pooled plasma sample were prepared over three days. All replicates were analysed  
4 using the ICP-MS using the same operating conditions. RSD values (both intra- and inter-day)  
5 for all 22 elements were low (range: 1.3 – 7.9 %), demonstrating satisfactory method  
6 repeatability/precision. The RSD values are deemed satisfactory by cross-checking with recent  
7 publications on ICP-QQQ-based metallomics methods.<sup>24, 25</sup> Next, to assess recovery, element  
8 concentrations obtained from samples spiked with multi-element standard before and after  
9 digestion were compared. All 22 elements have recoveries roughly within +/- 10 % threshold  
10 from 100 % (range: 89.9 – 105.2 %). This indicates satisfactory recovery of the entire analytical  
11 workflow. Additionally, it was also confirmed in this study that all elements analysed have  
12 baseline equivalent concentrations lower than their quantified concentrations in the pooled  
13 plasma sample, and that the calibration curves have  $R^2$  values  $> 0.9995$  which demonstrates  
14 good linearity.

15 However, we note that there were also some biologically relevant elements not quantifiable  
16 using our analytical workflow. Prominent examples include mercury as well as halogens like  
17 iodine, where additional steps and reagents may be required to counter issues with stability,  
18 memory effects, etc.<sup>26, 27</sup> Nonetheless, together with the satisfactory precision, recovery, and  
19 good analyte coverage of 22 elements, this metallomics workflow without the need for  
20 microwave digestion was simple and efficient. Thus, we applied it on the plasma samples of  
21 AMI patients and healthy controls to generate their metallomic profiles first consisting of  
22 elemental concentration data. Relevant element-pair product/ratios were also calculated. The  
23 12 essential elements studied here are Ca, Co, Cu, Fe, K, Mg, Mn, Na, P, S, Se, and Zn. The  
24 10 non-essential or toxic elements are Al, As, Ba, Cd, Cr, Ni, Rb, Sr, U, V. As a whole,



1   metallomic profiles comprising both elemental concentrations and element-pair product or  
2   ratios (30 metallomic features in total) were generated for each sample.

### 3   3.2. *Baseline characteristics and their associations with the metallome*

4       The baseline characteristics (including demographic characteristics, medical history related  
5   to the disease, as well as traditional cardiovascular risk factors and predictors of AMI and  
6   adverse events) of the study populations are summarised in Table 1. As the healthy controls  
7   were age-matched to the AMI cases, there are no statistically significant differences ( $p > 0.05$ )  
8   in age distributions between the AMI and healthy groups. However, the distributions of gender,  
9   smoking status, and race were found to be significantly different between the two groups ( $p <$   
10   0.0001). Next, for the medical history (Table 1), they are closely matched between AMI and  
11   control groups, with the only exception being dyslipidemia ( $p < 0.001$ ). For variables such as  
12   troponin T as measured via the high-sensitivity test (hsTnT) and N-terminal-pro hormone brain  
13   natriuretic peptides (NTproBNP), the highly significant differences are expected as they are  
14   biomarkers of AMI, and positive troponin was also an inclusion criterion for the AMI cases.  
15   As for other traditional cardiovascular risk factors, several of them (diastolic blood pressure  
16   (DBP), systolic blood pressure (SBP), high-density lipoprotein-cholesterol (HDL-C), white  
17   blood cell count (WBC), and creatinine levels are also statistically significant variables ( $p <$   
18   0.0001).

19       We note that the above variables could be possible confounders in this metallomics study.  
20   As such, before comparing the metallomic profiles between the AMI and healthy groups, we  
21   determined whether the aforementioned demographic characteristics and traditional CVD risk  
22   factors were independent determinants of plasma levels of the metallomic features. For that  
23   purpose, we fitted a linear model with each metallomics feature as the dependent variable and  
24   the demographic characteristics and traditional CVD risk biomarkers as independent variables.

1 Backwards elimination was performed to remove non-significant independent variables until  
2 all variables remaining in the model had  $p$ -values  $< 0.05$ . The  $\beta$  coefficients and significance  
3 levels of the determinants are summarised in Table 2. The determinants identified for each  
4 metallomic feature would then be included as covariates for ANCOVA when assessing  
5 statistical differences between AMI versus healthy in the next section.

6 Regardless, with reference to Table 2, various noteworthy associations of metallomic  
7 features with demographic characteristics and cardiovascular risk factors were identified.  
8 Firstly, smoking status is associated with the greatest number of metallomic features, and  
9 predominantly in the non-essential or toxic elements (*i.e.*, Al, Cd, Rb, Sr, U, V; all  $p < 0.01$ ).  
10 This could be expected as several of these elements are found in tobacco, cigarette paper, filters,  
11 and cigarette smoke (except U).<sup>28, 29</sup> It has also been revealed that the levels of these elements  
12 in circulation are affected by smoking, and they are linked to the disturbance of metal  
13 homeostasis and the pathogenesis of diseases.<sup>28, 29</sup> Moreover, out of the essential elements, Zn  
14 was also negatively associated with current smokers. This decrease could either be attributed  
15 to the link between Zn and nicotinic receptors stimulation (lower Zn levels =  
16 cause/predisposition of smoking),<sup>30</sup> or attributed to increased blood Cd concentration which  
17 induces expression of metallothionein binding of both Cd and Zn (lower Zn levels = effect of  
18 smoking).<sup>28, 31</sup> This is particularly relevant to our study on AMI as smoking-induced lowered  
19 Zn levels may lead to cellular ageing (oxidative stress) and increases the risk of hypertension.<sup>32</sup>

20 Secondly, three other pertinent metal-cardiovascular risk factor associations are (1)  
21 increasing Cu with lowering of cholesterol and increase in LDL-C, (2) increasing As with  
22 lowering of white blood cell levels, and (3) increasing Cu/Zn ratio with increasing creatinine  
23 (all  $p < 0.01$ ). For Cu, it has been reported that Cu deficiency is associated with increased total  
24 cholesterol.<sup>33</sup> While the direction of association in our study matches for total cholesterol  
25 levels, it was the opposite for LDL-C. Nevertheless, this could imply that an increased LDL-C

1 may not be a true artefact of Cu deficiency, but it could be oxidised LDL instead. This  
2 observation could be specific to our study on AMI patients, and the postulation could possibly  
3 be explained by Cu's promotion of LDL-C oxidation.<sup>34,35</sup> Next, for As, its negative association  
4 with white blood cell levels could be expected as various reports have revealed that arsenicosis  
5 or As exposure is associated with the prevalence of leukopenia<sup>36</sup> since As drives apoptosis in  
6 human lymphocytes via mechanisms related to oxidative stress, cytokine production, etc.<sup>37</sup>  
7 This is of relevance as an elevated WBC count has been directly associated with CHD and  
8 CVD adverse events in the African-American and White populations.<sup>38</sup> Thus, while As's  
9 toxicity makes high As levels undesirable, it could also be possible to observe higher levels of  
10 As in healthy people than AMI patients due to As's control of WBC counts. Finally, for the  
11 positive association of Cu/Zn ratio with creatinine, it serves to highlight the possible  
12 complications with renal issues since creatinine is an indicator of kidney malfunctions. Lower  
13 Zn has also previously been found in patients with end-stage renal disease while creatinine was  
14 shown to be a determinant of plasma Cu levels, augmenting our hypothesis.<sup>39</sup>

### 15 *3.3. Statistical comparisons of metallomic profiles between AMI and healthy, and across 3* 16 *time-points*

17 Mann Whitney test was first employed to identify metallomic features which are  
18 significantly different in AMI patients. Table 3 summarises their distributions, the *p*-values, as  
19 well as the direction of change in terms of the composition in AMI patients (measured at T1:  
20 24 – 48 hours post-PCI) compared to the healthy. To reduce bias and assess for the possible  
21 attenuating influence of the determinants on each metallomic feature, adjusted *p*-values from  
22 ANCOVA were also obtained and are provided in Table 3. To augment conjectures made  
23 regarding co-acting elements, Spearman correlation analysis between element levels was also  
24 done and results are summarised in a correlation heatmap (Figure 1). For the significantly  
25 altered metallomic features, further assessment on their changes across 3 time-points was also

1 done to determine if their dysregulation persists after 1 and 6 months (T2, and T3 respectively).  
2 For that purpose, Friedman test (non-parametric version of repeated-measures ANOVA) was  
3 applied to the longitudinal data to test for any significant changes (Table 4). Violin plots were  
4 also generated to visualise their trajectories (Figure 2). It is noted here that the simpler repeated  
5 measures test was used instead of more popular and robust options like the generalised linear  
6 mixed-effects model or the growth curve model based on characteristics of our data: (1) small  
7 number of time-points which we will assess as discrete time-points, (2) complete and no  
8 missing data, (3) simple design, comparison across time-points without assessing additional  
9 between/within-subjects factors.

### 10 3.3.1. *Ambivalent relationships of essential element levels with AMI*

11 As a whole, out of the 12 essential elements assessed using the Mann Whitney test, the  
12 AMI patients had significantly elevated Cu, Mg, and Na levels in their blood plasma as  
13 compared to the healthy controls, while Fe, P, and Se were decreased in levels (all  $p < 0.05$ ;  
14 Table 3). However, the  $p$ -value for Mg was attenuated to a non-significant level when  
15 ANCOVA was done. We therefore also exclude Mg as a significant variable for AMI risk. For  
16 the rest of the essential elements, significant differences in distributions are expected. Also, out  
17 of these essential elements, Cu and Se levels were significantly different at the different time-  
18 points ( $p < 0.0001$  and  $0.05$  respectively; Table 4), although detected effect sizes were  
19 considered small ( $0.10$  and  $0.04$  respectively). The possible trajectory of hsTnT, a more specific  
20 and choicer biomarker of AMI, is included in Figure 4 for comparison purposes. Since troponin  
21 T are released because of cardiac injury and myocardial necrosis (*i.e.*, consequence of AMI  
22 instead of cause), their serum levels peak 24-48 hours and return to baseline over 10-14 days.<sup>40</sup>  
23 Their trajectory of drastic decrease at T2 and T3 as shown in Figure 4 is thus expected. By  
24 extension, we expect that specific markers elevated/decreased due to AMI onset or progression  
25 could show observable trajectories as well. Thus, we determined that Cu and Se could be more

1 specific markers associated with the defence/response mechanism in AMI, on top of their roles  
2 in increasing general cardiovascular risk. On the other hand, significantly altered essential  
3 elements in AMI patients that did not have their levels returned closer to levels in healthy  
4 subjects after 6 months (T3) could be less specific risk factors. This applies to Mg, Na, Fe, and  
5 P. More experiments testing the levels of Cu and Se immediately after hospitalisation due to  
6 chest pain, and before/after surgical intervention may be required to understand their changes  
7 better. We discuss each significantly altered essential element in the following paragraphs in  
8 greater detail.

9 Firstly, for Na, the observed elevated Na levels in AMI patients ( $p < 0.05$ ) is consistent  
10 with the literature, with the predominant view being that Na is a risk factor of CHD through  
11 increasing blood pressure and causing hypertension.<sup>41</sup> Secondly, we observed lower Se levels  
12 in AMI patients ( $p < 0.01$ ), which is also consistent with various meta-analyses on CVD and  
13 CHD.<sup>42-44</sup> Available evidence indicates that the role of Se in human health and CVD is mostly  
14 attributed to its presence in antioxidant and redox-relevant selenoproteins, *e.g.*, glutathione  
15 peroxidase, thioredoxin reductase.<sup>45</sup> Despite that, supplementation trials did not find any  
16 significant protective effect of Se supplementation on CVD and adverse outcomes including  
17 AMI.<sup>45</sup> Meanwhile, the non-significant linear association between Se and the lipid profile  
18 variables found in this work also supported such studies reporting that Se supplementation does  
19 not have effects on an aberrant lipid profile.<sup>46</sup> Our work also suggests that the previous link  
20 between Se and aberrant lipid profiles could also be associated with Se's link with Cu instead.  
21 The AMI Cu/Se levels and significant difference ( $p < 0.0001$ ) observed in this work is firstly  
22 in line with a previous report<sup>15</sup>, and secondly also showed linear associations for cholesterol  
23 and LDL-C. Additionally, with reference to Table 4, we observed a significant increase in Se  
24 levels from a median of 90.31 to 94.11 ng/mL in AMI patients at T2, which remained consistent  
25 at T3. However, Se concentration at T3 (median = 94.50 ng/mL) is still significantly lower than

1 in healthy patients (median 99.98 ng/mL;  $p < 0.05$ ). Thus, we postulate that the lower Se levels  
2 at T1 could be related to the cardiac surgery (PCI), which may have served as an ischemic  
3 stimulus that activated inflammatory responses, thereby aggravating the decrease of circulating  
4 Se intra/-post-operation.<sup>47, 48</sup>

5 Besides Se and Na, the other significantly altered essential elements (Cu, Fe, and P) seemed  
6 to contradict the predominant views based on earlier research in cardiovascular health. In  
7 contrast, our results augment the standpoint that essential elements should have ambivalent  
8 associations with disease risk via a U- or J-shaped trend. This U/J-shaped trend is commonly  
9 associated with the dose-response relationship concept in toxicology, but it also applies to  
10 essential substances such as vitamins as well as essential trace elements.<sup>49</sup> While  
11 overload/overexposure of these elements may be toxic and incur health issues, the deficiency  
12 of these essential elements may also cause adverse effects.<sup>49</sup> Our results may suggest a need to  
13 redefine the normal range for these essential elements, and that the predictive value of these  
14 circulating element levels for AMI may be improved by accounting for the U/J-shaped trend.

15 Firstly, for Cu, Cu depletion/deficiency was more commonly reported as a risk factor of  
16 the CVDs and even a leading cause of CHD particularly.<sup>50-52</sup> Cu plays essential roles in many  
17 biological processes (*e.g.*, co-factor for many antioxidant enzymes, involvement in glycation,  
18 possible involvement in cytochrome and mitochondria activity, regulation of blood vessels'  
19 response to inflammatory stimuli), and its deficiency could dysregulate these processes, leading  
20 to the promotion of disease.<sup>50, 51</sup> However, there has also been contradicting reports on elevated  
21 circulating Cu found in CHD patients in large-scale studies from the USA and Finland, as well  
22 as in a smaller study in Iran.<sup>53-56</sup> The results from our study agree with these reports (Table 3).  
23 Interestingly, when comparing between these studies as well as present work, it seemed that  
24 the elevated Cu was consistently seen in both prospective and cross-sectional studies.<sup>53-56</sup> This

1 indicates that Cu concentrations were elevated in CHD patients when measured both before  
2 and after atherosclerotic events. This allows us to conclude that elevated circulating Cu is likely  
3 a causal/risk factor. Nevertheless, we cannot exclude the possibility that elevated Cu is also a  
4 consequence of atherosclerotic events, as a previous study monitoring serum Cu concentrations  
5 of AMI patients over 14 days after infarct reported that serum Cu levels gradually attained peak  
6 value on the 7<sup>th</sup> day after an initial rise on day 1 without returning to normal levels after 2  
7 weeks.<sup>57</sup> With reference to Table 4 and Figure 2, our study also showed that Cu levels remained  
8 elevated in AMI patients at T1 (24-48 hours after PCI) and T2 (1-month after T1), but  
9 significantly falls during the 6-month follow-up ( $p < 0.0001$ ). While the effect size was small  
10 ( $W = 0.10$ ), the result still demonstrates that the observed rise in Cu could be in part a specific  
11 defence mechanism in response to myocardial damage.<sup>57</sup> Thus, we conclude that Cu could be  
12 associated with AMI as both a cause and a consequence.

13 Secondly, for Fe, it was reported that the conventional iron hypothesis supported by various  
14 studies was first proposed by Sullivan, that iron depletion protects against CHD.<sup>58</sup> Though  
15 there were also reports with contradicting conclusions. However, it was more recently  
16 recognised that both Fe overload and deficiency are associated with increased cardiovascular  
17 morbidity and mortality.<sup>59</sup> In the Ludwigshafen Risk and Cardiovascular Healthy (LURIC)  
18 study, a J-shaped association of Fe load was observed and proposed.<sup>60</sup> Our work, showing  
19 lower Fe levels in AMI ( $p < 0.01$ ), adds to the overall discussion regarding this ambivalent  
20 relationship between Fe and disease. Additionally, despite both Cu and Fe possibly having  
21 ambivalent relationships with AMI, such ambivalence does not necessarily mask the  
22 association of Fe/Cu ratio with AMI. In contrast, our results showed that Fe/Cu may be a more  
23 sensitive risk marker than either Cu or Fe alone ( $p < 0.0001$ ; Table 3). However, while  
24 numerous Fe-Cu interactions were uncovered over recent years, it is unclear how the CVDs

1 and AMI are affected. Nevertheless, the potential of Fe/Cu ratio as a sensitive marker is further  
2 revealed via multivariate analysis and classification modelling in *section 3.4* below.

3 Finally, for P, high phosphate levels (*i.e.*, hyperphosphatemia) has been consistently linked  
4 with cardiac calcification, left ventricular hypertrophy, and cardiovascular events and death,  
5 regardless of comorbidity with chronic kidney disease (CKD).<sup>61-63</sup> Concerning AMI in  
6 particular, the pro-atherogenic mechanism and formation of atherosclerotic plaques caused by  
7 phosphate excess is still unclarified and controversial.<sup>63</sup> However, instead of being cardio-  
8 protective, our work shows that P levels are significantly lower in AMI patients as compared  
9 to the healthy controls ( $p < 0.05$ ; Table 3). Our observations validate the findings by Hayward  
10 et al., who reportedly was the first to identify that low P level is also a risk factor for heart  
11 disease in adults in a large-scale UK-wide retrospective cohort study.<sup>64</sup> Next, an approach using  
12 Mg supplementation had been introduced to target hyperphosphatemia-associated  
13 cardiovascular risk in CKD patients by Sakaguchi and coworkers.<sup>21, 65</sup> As such, to indirectly  
14 investigate the possible balance between Mg and P with AMI and whether increased Mg levels  
15 is linked with lowered hyperphosphatemia-linked AMI, we compared the P/Mg ratios.  
16 However, our study showed that AMI patients have a significantly lower P/Mg ratio than the  
17 healthy ( $p < 0.001$ ; Table 3). This contradicts previous findings by Sakaguchi and coworkers,  
18 suggesting that the high P and low Mg correlation could be specific to CKD patients. We thus  
19 suggest that further large-scale studies perform subgroup analysis of AMI patients with and  
20 without CKD when assessing the P and Mg relationship. A more nuanced approach is also  
21 needed when considering Mg supplementation for reducing cardiovascular mortality in CKD  
22 patients, or vice versa. Finally, besides Mg, Ca has also been linked with P, and a deranged Ca-  
23 P metabolism was identified as a major non-traditional cardiovascular risk factor for both CKD  
24 patients and even among individuals with intact renal function.<sup>66, 67</sup> The link between Ca and  
25 P is multi-pronged, including Ca's involvement in the metabolic regulation of phosphate, high



1 phosphate contribution to vascular calcification, and valve calcification via pathological and  
2 concurrent depositions of Ca-P salts on cardiac valves.<sup>63, 68</sup> However, in the current study, there  
3 is no significant association of circulating Ca levels with AMI cases ( $p > 0.05$ ; Table 3), and  
4 we saw no significant difference in Ca×P products between groups after adjustments for  
5 covariates. This is contrary to previous results regarding coronary artery calcification and  
6 coronary heart disease risk.<sup>13, 14</sup> Thus, while our study shows that Ca and P levels are indeed  
7 correlated (Figure 1), we can only conclude Ca's involvement in phosphate metabolism (or  
8 vice versa). On the other hand, the utility of the Ca×P product as a CVD or AMI biomarker is  
9 limited and requires re-assessment.

### 10 3.3.2. *Non-essential or toxic elements, except As, are not specifically associated with AMI*

11 Through the Mann Whitney test, Al, Ba, Rb, and Sr were found to be significantly elevated  
12 in AMI patients, while As levels were lowered. However, for most of them (Al, Rb, and St),  
13 their  $p$ -values were attenuated to non-significance upon ANCOVA. This was expected, as  
14 smoking status is a confounder for the various elements (discussed in more detail in *section*  
15 *3.2*). Based on our findings, we suggest future studies definitively include smoking as a  
16 covariate for these elements to avoid inflating their roles in diseases.

17 Next, as for Ba, its levels were significantly higher (adjusted  $p < 0.05$ ) in AMI patients. Ba  
18 has been seldom associated with AMI, and the few epidemiological studies assessing its link  
19 to the CVDs (especially from drinking water) did not reveal Ba as a risk factor of clinical  
20 significance.<sup>69-71</sup> The reported cardiovascular effects by Ba include adverse effects on heart  
21 rhythm and hypotension, which were suggested to be caused by Ba-induced hypokalemia.<sup>72</sup>  
22 However, correlation analysis did not reveal significant linear associations between Ba and K  
23 in our study populations (Figure 1). Moreover, the  $p$ -value from the univariate comparison  
24 between AMI and healthy was attenuated close to borderline significance after adjustments for  
25 race and white blood cell levels. Thus, since our study lack information regarding the level of

1 exposure to Ba through any possible routes (*e.g.*, drinking water or clinical sources like Ba  
2 contrast solution used in radiologic examinations), we could not make further assessments  
3 regarding the specific role of Ba in AMI. Regardless, Ba remains to be of limited significance  
4 as a risk factor for AMI.

5 For As, unexpectedly, we found lower As levels in AMI patients than healthy, which *p*-  
6 value remained significant after ANCOVA ( $p < 0.001$ ). There is ample evidence that CHD risk  
7 is positively associated with inorganic As exposure (via drinking water, rice, etc).<sup>73-76</sup> Other  
8 than the use of As trioxide as a chemotherapeutic or antineoplastic drug, As does not have any  
9 known benefits to human health.<sup>77</sup> Since history of malignancy within the last 12-months was  
10 an exclusion criterion for the study's sampling design, we may exclude As bioaccumulation  
11 from such exposures as a possible explanation. Alternatively, the lowered As could be an  
12 indirect response to effects induced by the PCI. This is supported by our observation that As  
13 levels at T2 and T3 were significantly increased from T1 based on the repeated measures  
14 ANOVA and post-hoc pairwise comparisons ( $p < 0.0001$ ), and that levels at T3 were not  
15 significantly different from healthy based on a Mann Whitney test ( $p > 0.05$ ). Further studies  
16 on As metabolism in AMI onset/intervention strategies are needed to evaluate this possibility.  
17 Regardless, the non-significant difference between As levels in AMI patients and T3 versus in  
18 healthy subjects could be attributed to the biospecimen being studied. While chronic low As  
19 exposure may result in As accumulation in blood, there are notable differences between the  
20 profiles of As species in the plasma and the urine, and these different species could be  
21 indicators of sources of As (organic forms from dietary sources, or inorganic forms from  
22 environmental exposure).<sup>78</sup> Additionally, methylated forms of As have been suggested as  
23 indicators of effective biotransformation/detoxification of the inorganic As species. Other  
24 organic species such as As-betaine, which are principally introduced from seafood and  
25 agricultural products, also has low toxicity despite being found in human serum.<sup>79</sup> Finally,

1 previous work also reported different As speciation profiles in different cardiovascular tissues  
2 of CHD patients.<sup>80</sup> Thus, we recommend future work to perform As speciation analysis instead  
3 of mere total As measurements in circulation, to more accurately define the contribution of As  
4 in AMI.

### 5 *3.4. Classification modelling and performance of metallomics as AMI biomarker*

6 Notwithstanding the possible diverse roles of the various elements as either non-specific  
7 and non-independent risk factors or as more specific markers related to cardiac injury and  
8 surgery, we performed classification modelling using all metallomic features to assess the  
9 performance of metallomics as a biomarker. Age and the traditional cardiovascular risk factors  
10 measured in routine tests (DBP, SBP, triglyceride, cholesterol, HDL-C, LDL-C, WBC, platelet,  
11 creatinine) were also included in the modelling for comparison purposes. A total of 40 variables  
12 (30 metallomic features + 10 clinical variables) was explored. The ROC curves based on  
13 models formed with varying numbers of features were generated, and predictive accuracies  
14 were also calculated as an average based on 30 iterations (Figure 3).

15 As reflected in Figures 3A and 3B, the best performing model with an area under curve  
16 (AUC) of 0.942 (95% CI 0.889 - 0.970) and predictive accuracy of 87% was made up of a  
17 combination of 10 variables. The top 10 important features selected for the random forest  
18 classifier are thus also shown in Figure 3A. While the top 3 variables are clinical variables  
19 (WBC, HDL-C, and cholesterol), the following variables are all metallomic features (Fe/Cu,  
20 Ca/Mg, Fe, P/Mg, Zn, As, Se). This suggests the potential of metallomic features for the  
21 replacement or concurrent usage with current risk factors in predicting AMI.

22 Next, the identification of Fe/Cu ratio as an important variable augmented the univariate  
23 results in suggesting it as a potentially more sensitive biomarker for AMI than the 2 metals  
24 individually. Also, the inclusion of Cu, Se, and As as important features may also confer

1 specificity of the model for AMI prediction or prognosis, based on postulations regarding their  
2 changes at T2 and T3 as discussed earlier. However, out of the important variables, Ca/Mg and  
3 Zn were not found to be significantly altered in AMI based on univariate comparisons. In line  
4 with random forest classifiers' non-linear nature, our results suggest that Ca/Mg and Zn's  
5 relationships with AMI, at least in the populations studied, could be non-linear.

#### 6 **4. Conclusions**

7 In summary, a total of 30 metallomic features (12 essential elements, 10 non-essential or  
8 toxic elements, as well as 8 element-pair product/ratios) were profiled via a validated and  
9 efficient ICP-MS/MS-based workflow. Greater insights into the mechanisms and ambivalent  
10 relationships of the essential elements (*e.g.*, Cu, Fe, and P) with health and disease were  
11 revealed based on our results and comparisons with literature. Additionally, changes in the  
12 AMI metallomic profile across 3 time-points revealed possible roles of Fe, Na, and P as stable  
13 but non-specific risk factors of AMI, and Cu and Se as more specific biomarkers. Based on the  
14 analysis of product/ratios calculated from related essential element pairs, more sensitive  
15 variables are identified (*e.g.*, Cu/Se, Fe/Cu). Classification modelling also revealed several  
16 metallomic features as potential biomarkers that may be used in replacement of or alongside  
17 traditional cardiovascular risk factors for AMI prediction.

18 Finally, our study has some limitations. Firstly, the sample size was relatively small, and  
19 the proposed U/J-shaped trend for the essential elements' ambivalent associations could not be  
20 tangibly visualised. Secondly, while the longitudinal analysis across 3 time-points provided  
21 intriguing hypotheses on element concentrations' causal/consequential links to AMI, further  
22 studies over longer periods and also specifically on closer time-points before and after  
23 intervention are required to confirm the hypotheses. Speciation analysis, especially for  
24 elements such as Se and As, are also recommended to better understand their modes of action  
25 in AMI for more specific therapeutic strategies and biomarker development.

## 1 **Supplementary Materials**

### 2 Supplementary Information (.docx)

3 Table S1: Instrument settings for the Agilent 8900 ICP-QQQ in different CRC modes.

4 Table S2: Mass shifts, ISTD, and CRC modes used for the metallomics analysis.

## 5 **Funding**

6 This work was supported by the Ministry of Education of Singapore (grant number: R-  
7 143-000-B48-114).

## 8 **Acknowledgments**

9 The authors would like to thank the engineers and product specialists from Agilent  
10 Technologies Singapore Pte Ltd for the technical support and advice.

## 11 **Conflicts of Interest**

12 The authors declare no conflicts of interest.

13

## 1 References

- 2 1. Douglas P. Zipes, P. L., Robert O. Bonow, Douglas L. Mann, Gordon F. Tomaselli,  
3 *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 11 ed.; Elsevier: 2018.
- 4 2. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195  
5 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease  
6 Study 2017. *Lancet* 2018; 392: 1736–88 **2018**, 392 (10159), 1736-88.
- 7 3. Chowdhury, R.; Ramond, A.; O’Keeffe, L. M.; Shahzad, S.; Kunutsor, S. K.; Muka,  
8 T.; Gregson, J.; Willeit, P.; Warnakula, S.; Khan, H.; Chowdhury, S.; Gobin, R.; Franco,  
9 O. H.; Di Angelantonio, E., Environmental toxic metal contaminants and risk of cardiovascular  
10 disease: systematic review and meta-analysis. *BMJ* **2018**, k3310.
- 11 4. Edet Ekpenyong, C., Essential Trace Element and Mineral Deficiencies and  
12 Cardiovascular Diseases: Facts and Controversies. *International Journal of Nutrition and Food*  
13 *Sciences* **2017**, 6 (2), 53.
- 14 5. Lim, S. Y.; Selvaraji, S.; Lau, H.; Li, S. F. Y., Application of omics beyond the central  
15 dogma in coronary heart disease research: A bibliometric study and literature review.  
16 *Computers in Biology and Medicine* **2022**, 140, 105069.
- 17 6. Maret, W., An Appraisal of the Field of Metallomics and the Roles of Metal Ions in  
18 Biochemistry and Cell Signaling. *Applied Sciences* **2021**, 11 (22).
- 19 7. Chen, B.; Hu, L.; He, B.; Luan, T.; Jiang, G., Environmetallomics: Systematically  
20 investigating metals in environmentally relevant media. *TrAC Trends in Analytical Chemistry*  
21 **2020**, 126.
- 22 8. Walkner, C.; Gratzer, R.; Meisel, T.; Bokhari, S. N. H., Multi-element analysis of  
23 crude oils using ICP-QQQ-MS. *Organic Geochemistry* **2017**, 103, 22-30.
- 24 9. Paseka, R. E.; Bratt, A. R.; MacNeill, K. L.; Burian, A.; See, C. R., Elemental Ratios  
25 Link Environmental Change and Human Health. *Frontiers in Ecology and Evolution* **2019**, 7.
- 26 10. Dai, Q.; Shu, X.-O.; Deng, X.; Xiang, Y.-B.; Li, H.; Yang, G.; Shrubsole, M. J.; Ji,  
27 B.; Cai, H.; Chow, W.-H.; Gao, Y.-T.; Zheng, W., Modifying effect of calcium/magnesium  
28 intake ratio and mortality: a population-based cohort study. *BMJ Open* **2013**, 3 (2), e002111.
- 29 11. Hibler, E. A.; Zhu, X.; Shrubsole, M. J.; Hou, L.; Dai, Q., Physical activity, dietary  
30 calcium to magnesium intake and mortality in the National Health and Examination Survey  
31 1999–2006 cohort. *International Journal of Cancer* **2020**, 146 (11), 2979-2986.

- 1 12. Pereira, D. D. C.; Lima, R. P. A.; De Lima, R. T.; Gonçalves, M. D. C. R.; De Moraes,  
2 L. C. S. L.; Franceschini, S. D. C. C.; Filizola, R. G.; De Moraes, R. M.; Asciutti, L. S. R.;  
3 Costa, M. J. D. C., Association between obesity and calcium:phosphorus ratio in the habitual  
4 diets of adults in a city of Northeastern Brazil: an epidemiological study. *Nutrition Journal*  
5 **2013**, *12* (1), 90.
- 6 13. Kwak, S. M.; Kim, J. S.; Choi, Y.; Chang, Y.; Kwon, M. J.; Jung, J. G.; Jeong, C.;  
7 Ahn, J.; Kim, H. S.; Shin, H.; Ryu, S., Dietary intake of calcium and phosphorus and serum  
8 concentration in relation to the risk of coronary artery calcification in asymptomatic adults.  
9 *Arterioscler Thromb Vasc Biol* **2014**, *34* (8), 1763-9.
- 10 14. Foley, R. N.; Collins, A. J.; Ishani, A.; Kalra, P. A., Calcium-phosphate levels and  
11 cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in  
12 Communities (ARIC) Study. *Am Heart J* **2008**, *156* (3), 556-63.
- 13 15. Mironczuk, A.; Kapica-Topczewska, K.; Socha, K.; Soroczynska, J.; Jamiolkowski,  
14 J.; Kulakowska, A.; Kochanowicz, J., Selenium, Copper, Zinc Concentrations and Cu/Zn,  
15 Cu/Se Molar Ratios in the Serum of Patients with Acute Ischemic Stroke in Northeastern  
16 Poland-A New Insight into Stroke Pathophysiology. *Nutrients* **2021**, *13* (7).
- 17 16. Malavolta, M.; Giacconi, R.; Piacenza, F.; Santarelli, L.; Cipriano, C.; Costarelli,  
18 L.; Tesei, S.; Pierpaoli, S.; Basso, A.; Galeazzi, R.; Lattanzio, F.; Mocchegiani, E., Plasma  
19 copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in  
20 elderly population. *Biogerontology* **2010**, *11* (3), 309-319.
- 21 17. Malavolta, M.; Piacenza, F.; Basso, A.; Giacconi, R.; Costarelli, L.; Mocchegiani,  
22 E., Serum copper to zinc ratio: Relationship with aging and health status. *Mech Ageing Dev*  
23 **2015**, *151*, 93-100.
- 24 18. Collins, J. F.; Prohaska, J. R.; Knutson, M. D., Metabolic crossroads of iron and copper.  
25 *Nutrition Reviews* **2010**, *68* (3), 133-147.
- 26 19. Cook, N. R., Joint Effects of Sodium and Potassium Intake on Subsequent  
27 Cardiovascular Disease. *Archives of Internal Medicine* **2009**, *169* (1), 32.
- 28 20. Baer, D. J.; Althouse, A.; Hermann, M.; Johnson, J.; Maki, K. C.; Marklund, M.;  
29 Vogt, L.; Wesson, D.; Stallings, V. A., Targeting the Dietary Na:K Ratio—Considerations for  
30 Design of an Intervention Study to Impact Blood Pressure. *Advances in Nutrition* **2022**, *13* (1),  
31 225-233.
- 32 21. Sakaguchi, Y.; Fujii, N.; Shoji, T.; Hayashi, T.; Rakugi, H.; Iseki, K.; Tsubakihara,  
33 Y.; Isaka, Y., Magnesium Modifies the Cardiovascular Mortality Risk Associated with

- 1 Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study. *PLoS ONE* **2014**,  
2 9 (12), e116273.
- 3 22. Tanvir, E. M.; Komarova, T.; Comino, E.; Sumner, R.; Whitfield, K. M.; Shaw, P.  
4 N., Effects of storage conditions on the stability and distribution of clinical trace elements in  
5 whole blood and plasma: Application of ICP-MS. *J Trace Elem Med Biol* **2021**, 68, 126804.
- 6 23. Robin, X.; Turck, N.; Hainard, A.; Tiberti, N.; Lisacek, F.; Sanchez, J.-C.; Müller,  
7 M., pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC*  
8 *Bioinformatics* **2011**, 12 (1), 77.
- 9 24. Konz, T.; Migliavacca, E.; Dayon, L.; Bowman, G.; Oikonomidi, A.; Popp, J.; Rezzi,  
10 S., ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological  
11 Variability of the Human Ionome. *Journal of Proteome Research* **2017**, 16 (5), 2080-2090.
- 12 25. Meyer, S.; Markova, M.; Pohl, G.; Marschall, T. A.; Pivovarov, O.; Pfeiffer, A. F.  
13 H.; Schwerdtle, T., Development, validation and application of an ICP-MS/MS method to  
14 quantify minerals and (ultra-)trace elements in human serum. *J Trace Elem Med Biol* **2018**, 49,  
15 157-163.
- 16 26. McShane, W. J.; Pappas, R. S.; Wilson-McElprang, V.; Paschal, D., A rugged and  
17 transferable method for determining blood cadmium, mercury, and lead with inductively  
18 coupled plasma-mass spectrometry. *Spectrochimica Acta Part B: Atomic Spectroscopy* **2008**,  
19 63 (6), 638-644.
- 20 27. Flores, E. M. M.; Mello, P. A.; Krzyzaniak, S. R.; Cauduro, V. H.; Picoloto, R. S.,  
21 Challenges and trends for halogen determination by inductively coupled plasma mass  
22 spectrometry: A review. *Rapid Commun Mass Spectrom* **2020**, 34 Suppl 3, e8727.
- 23 28. Bernhard, D.; Rossmann, A.; Wick, G., Metals in cigarette smoke. *IUBMB Life*  
24 (*International Union of Biochemistry and Molecular Biology: Life*) **2005**, 57 (12), 805-809.
- 25 29. Bernhard, D.; Rossmann, A.; Henderson, B.; Kind, M.; Seubert, A.; Wick, G.,  
26 Increased Serum Cadmium and Strontium Levels in Young Smokers. *Arteriosclerosis,*  
27 *Thrombosis, and Vascular Biology* **2006**, 26 (4), 833-838.
- 28 30. Nechifor, M., Magnesium and Zinc Involvement in Tobacco Addiction. *Journal of*  
29 *Addiction Research & Therapy* **2012**, 01 (S2).
- 30 31. Richter, P.; Faroon, O.; Pappas, R. S., Cadmium and Cadmium/Zinc Ratios and  
31 Tobacco-Related Morbidities. *International Journal of Environmental Research and Public*  
32 *Health* **2017**, 14 (10), 1154.



- 1 32. Suarez-Varela, M. M.; Llopis-González, A.; González Albert, V.; López-Izquierdo,  
2 R.; González-Manzano, I.; Cháves, J.; Biosca, V. H.; Martin-Escudero, J. C., Zinc and  
3 smoking habits in the setting of hypertension in a Spanish populations. *Hypertension Research*  
4 **2015**, *38* (2), 149-154.
- 5 33. L, J.; Lutsenko, S., The Role of Copper as a Modifier of Lipid Metabolism. InTech:  
6 2013.
- 7 34. Wagner, P.; Heinecke, J. W., Copper Ions Promote Peroxidation of Low Density  
8 Lipoprotein Lipid by Binding to Histidine Residues of Apolipoprotein B100, But They Are  
9 Reduced at Other Sites on LDL. *Arteriosclerosis, Thrombosis, and Vascular Biology* **1997**, *17*  
10 (11), 3338-3346.
- 11 35. Holvoet, P.; Mertens, A.; Verhamme, P.; Bogaerts, K.; Beyens, G.; Verhaeghe, R.;  
12 Collen, D. S.; Muls, E.; Van De Werf, F., Circulating Oxidized LDL Is a Useful Marker for  
13 Identifying Patients With Coronary Artery Disease. *Arteriosclerosis, Thrombosis, and*  
14 *Vascular Biology* **2001**, *21* (5), 844-848.
- 15 36. Islam, L.; Nabi, A.; Rahman, M.; Khan, M.; Kazi, A., Association of Clinical  
16 Complications with Nutritional Status and the Prevalence of Leukopenia among Arsenic  
17 Patients in Bangladesh. *International Journal of Environmental Research and Public Health*  
18 **2004**, *1* (2), 74-82.
- 19 37. Zarei, M. H.; Pourahmad, J.; Nassireslami, E., Toxicity of arsenic on isolated human  
20 lymphocytes: The key role of cytokines and intracellular calcium enhancement in arsenic-  
21 induced cell death. *Main Group Metal Chemistry* **2019**, *42* (1), 125-134.
- 22 38. Lee, C. D.; Folsom, A. R.; Nieto, F. J.; Chambless, L. E.; Shahar, E.; Wolfe, D. A.,  
23 White Blood Cell Count and Incidence of Coronary Heart Disease and Ischemic Stroke and  
24 Mortality from Cardiovascular Disease in African-American and White Men and Women:  
25 Atherosclerosis Risk in Communities Study. *American Journal of Epidemiology* **2001**, *154* (8),  
26 758-764.
- 27 39. Batista, M. N.; Cuppari, L.; De Fátima Campos Pedrosa, L.; Almeida, M. D. G.; De  
28 Almeida, J. B.; De Medeiros, A. C. Q.; Canziani, M. E. F., Effect of End-Stage Renal Disease  
29 and Diabetes on Zinc and Copper Status. *Biological Trace Element Research* **2006**, *112* (1), 1-  
30 12.
- 31 40. Jeremias, A., The utility of troponin measurement to detect myocardial infarction:  
32 review of the current findings. *Vascular Health and Risk Management* **2010**, 691.
- 33 41. O'Donnell, M.; Mente, A.; Yusuf, S., Sodium Intake and Cardiovascular Health.  
34 *Circulation Research* **2015**, *116* (6), 1046-1057.

- 1 42. Zhang, X.; Liu, C.; Guo, J.; Song, Y., Selenium status and cardiovascular diseases:  
2 meta-analysis of prospective observational studies and randomized controlled trials. *European*  
3 *Journal of Clinical Nutrition* **2016**, *70* (2), 162-169.
- 4 43. Flores-Mateo, G.; Navas-Acien, A.; Pastor-Barriuso, R.; Guallar, E., Selenium and  
5 coronary heart disease: a meta-analysis. *The American Journal of Clinical Nutrition* **2006**, *84*  
6 (4), 762-773.
- 7 44. Kuria, A.; Tian, H.; Li, M.; Wang, Y.; Aaseth, J. O.; Zang, J.; Cao, Y., Selenium  
8 status in the body and cardiovascular disease: a systematic review and meta-analysis. *Critical*  
9 *Reviews in Food Science and Nutrition* **2021**, *61* (21), 3616-3625.
- 10 45. Benstoem, C.; Goetzenich, A.; Kraemer, S.; Borosch, S.; Manzanares, W.; Hardy,  
11 G.; Stoppe, C., Selenium and Its Supplementation in Cardiovascular Disease—What do We  
12 Know? *Nutrients* **2015**, *7* (5), 3094-3118.
- 13 46. Ju, W.; Li, X.; Li, Z.; Wu, G. R.; Fu, X. F.; Yang, X. M.; Zhang, X. Q.; Gao, X. B.,  
14 The effect of selenium supplementation on coronary heart disease: A systematic review and  
15 meta-analysis of randomized controlled trials. *Journal of Trace Elements in Medicine and*  
16 *Biology* **2017**, *44*, 8-16.
- 17 47. Koszta, G.; Kacska, Z.; Szatmári, K.; Szerafin, T.; Fülesdi, B., Lower whole blood  
18 selenium level is associated with higher operative risk and mortality following cardiac surgery.  
19 *Journal of Anesthesia* **2012**, *26* (6), 812-821.
- 20 48. Stoppe, C.; Schälte, G.; Rossaint, R.; Coburn, M.; Graf, B.; Spillner, J.; Marx, G.;  
21 Rex, S., The intraoperative decrease of selenium is associated with the postoperative  
22 development of multiorgan dysfunction in cardiac surgical patients\*. *Critical Care Medicine*  
23 **2011**, *39* (8).
- 24 49. Moffett, D. B.; Mumtaz, M. M.; Sullivan, D. W.; Fowler, B. A., Chapter 10 - General  
25 Considerations of Dose-Effect and Dose-Response Relationships\*. In *Handbook on the*  
26 *Toxicology of Metals (Fourth Edition)*, Nordberg, G. F.; Fowler, B. A.; Nordberg, M., Eds.  
27 Academic Press: San Diego, 2015; pp 197-212.
- 28 50. Dinicolantonio, J. J.; Mangan, D.; O’Keefe, J. H., Copper deficiency may be a leading  
29 cause of ischaemic heart disease. *Open Heart* **2018**, *5* (2), e000784.
- 30 51. Klevay, L. M., Cardiovascular Disease from Copper Deficiency—A History. *The*  
31 *Journal of Nutrition* **2000**, *130* (2), 489S-492S.
- 32 52. Liu, Y.; Miao, J., An Emerging Role of Defective Copper Metabolism in Heart Disease.  
33 *Nutrients* **2022**, *14* (3).

- 1 53. Bagheri, B.; Akbari, N.; Tabiban, S.; Habibi, V.; Mokhberi, V., Serum level of copper  
2 in patients with coronary artery disease. *Niger Med J* **2015**, *56* (1), 39-42.
- 3 54. Ford, E. S., Serum Copper Concentration and Coronary Heart Disease among US  
4 Adults. *American Journal of Epidemiology* **2000**, *151* (12), 1182-1188.
- 5 55. Kunutsor, S. K.; Dey, R. S.; Laukkanen, J. A., Circulating Serum Copper Is Associated  
6 with Atherosclerotic Cardiovascular Disease, but Not Venous Thromboembolism: A  
7 Prospective Cohort Study. *Pulse* **2021**, *9* (3-4), 109-115.
- 8 56. Salonen, J. T.; Salonen, R.; Korpela, H.; Suntioinen, S.; Tuomilehto, J., Serum Copper  
9 and the Risk of Acute Myocardial Infarction: A Prospective Population Study in Men in  
10 Eastern Finland. *American Journal of Epidemiology* **1991**, *134* (3), 268-276.
- 11 57. Jain, V. K.; Mohan, G., Serum zinc and copper in myocardial infarction with particular  
12 reference to prognosis. *Biological Trace Element Research* **1991**, *31* (3), 317-322.
- 13 58. De Valk, B.; Marx, J. J. M., Iron, Atherosclerosis, and Ischemic Heart Disease. *Archives*  
14 *of Internal Medicine* **1999**, *159* (14), 1542.
- 15 59. Von Eckardstein, A., Iron in Coronary Heart Disease—J-Shaped Associations and  
16 Ambivalent Relationships. *Clinical Chemistry* **2019**, *65* (7), 821-823.
- 17 60. Grammer, T. B.; Scharnagl, H.; Dressel, A.; Kleber, M. E.; Silbernagel, G.; Pilz, S.;  
18 Tomaschitz, A.; Koenig, W.; Mueller-Myhsok, B.; März, W.; Strnad, P., Iron Metabolism,  
19 Hepcidin, and Mortality (the Ludwigshafen Risk and Cardiovascular Health Study). *Clinical*  
20 *Chemistry* **2019**, *65* (7), 849-861.
- 21 61. Foley, R. N., Phosphate Levels and Cardiovascular Disease in the General Population.  
22 *Clinical Journal of the American Society of Nephrology* **2009**, *4* (6), 1136-1139.
- 23 62. Kendrick, J.; Kestenbaum, B.; Chonchol, M., Phosphate and Cardiovascular Disease.  
24 *Advances in Chronic Kidney Disease* **2011**, *18* (2), 113-119.
- 25 63. Zhou, C.; Shi, Z.; Ouyang, N.; Ruan, X., Hyperphosphatemia and Cardiovascular  
26 Disease. *Front Cell Dev Biol* **2021**, *9*, 644363.
- 27 64. Hayward, N.; McGovern, A.; De Lusignan, S.; Cole, N.; Hinton, W.; Jones, S., U-  
28 shaped relationship between serum phosphate and cardiovascular risk: A retrospective cohort  
29 study. *PLOS ONE* **2017**, *12* (11), e0184774.

- 1 65. Sakaguchi, Y.; Hamano, T.; Obi, Y.; Monden, C.; Oka, T.; Yamaguchi, S.; Matsui,  
2 I.; Hashimoto, N.; Matsumoto, A.; Shimada, K.; Takabatake, Y.; Takahashi, A.; Kaimori,  
3 J.-Y.; Moriyama, T.; Yamamoto, R.; Horio, M.; Yamamoto, K.; Sugimoto, K.; Rakugi, H.;  
4 Isaka, Y., A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary  
5 Artery Calcification in Predialysis CKD. *Journal of the American Society of Nephrology* **2019**,  
6 *30* (6), 1073-1085.
- 7 66. Heine, G. H.; Nangaku, M.; Fliser, D., Calcium and phosphate impact cardiovascular  
8 risk. *European Heart Journal* **2013**, *34* (15), 1112-1121.
- 9 67. Block, G.; Port, F. K., THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR  
10 DISEASES IN CHRONIC KIDNEY DISEASE: Calcium Phosphate Metabolism and  
11 Cardiovascular Disease in Patients with Chronic Kidney Disease. *Seminars in Dialysis* **2003**,  
12 *16* (2), 140-147.
- 13 68. Massera, D.; Kizer, J. R.; Dweck, M. R., Mechanisms of mitral annular calcification.  
14 *Trends Cardiovasc Med* **2020**, *30* (5), 289-295.
- 15 69. Wones, R. G.; Stadler, B. L.; Frohman, L. A., Lack of effect of drinking water barium  
16 on cardiovascular risk factors. *Environmental health perspectives* **1990**, *85*, 355-359.
- 17 70. Kravchenko, J.; Darrah, T. H.; Miller, R. K.; Lyerly, H. K.; Vengosh, A., A review  
18 of the health impacts of barium from natural and anthropogenic exposure. *Environmental*  
19 *Geochemistry and Health* **2014**, *36* (4), 797-814.
- 20 71. Nigra, A. E.; Ruiz-Hernandez, A.; Redon, J.; Navas-Acien, A.; Tellez-Plaza, M.,  
21 Environmental Metals and Cardiovascular Disease in Adults: A Systematic Review Beyond  
22 Lead and Cadmium. *Current Environmental Health Reports* **2016**, *3* (4), 416-433.
- 23 72. Choudhury, H.; Cary, R.; World Health, O.; International Programme on Chemical,  
24 S., Barium and barium compounds. World Health Organization: Geneva, 2001.
- 25 73. States, J. C.; Srivastava, S.; Chen, Y.; Barchowsky, A., Arsenic and Cardiovascular  
26 Disease. *Toxicological Sciences* **2009**, *107* (2), 312-323.
- 27 74. Sobel, M. H.; Sanchez, T. R.; Jones, M. R.; Kaufman, J. D.; Francesconi, K. A.;  
28 Blaha, M. J.; Vaidya, D.; Shimbo, D.; Gossler, W.; Gamble, M. V.; Genkinger, J. M.; Navas-  
29 Acien, A., Rice Intake, Arsenic Exposure, and Subclinical Cardiovascular Disease Among US  
30 Adults in MESA. *Journal of the American Heart Association* **2020**, *9* (4).
- 31 75. Moon, K. A.; Oberoi, S.; Barchowsky, A.; Chen, Y.; Guallar, E.; Nachman, K. E.;  
32 Rahman, M.; Soheli, N.; D'Ippoliti, D.; Wade, T. J.; James, K. A.; Farzan, S. F.; Karagas,  
33 M. R.; Ahsan, H.; Navas-Acien, A., A dose-response meta-analysis of chronic arsenic

- 1 exposure and incident cardiovascular disease. *International Journal of Epidemiology* **2017**, *46*  
2 (6), 1924-1939.
- 3 76. Navas-Acien, A.; Sharrett, A. R.; Silbergeld, E. K.; Schwartz, B. S.; Nachman, K.  
4 E.; Burke, T. A.; Guallar, E., Arsenic Exposure and Cardiovascular Disease: A Systematic  
5 Review of the Epidemiologic Evidence. *American Journal of Epidemiology* **2005**, *162* (11),  
6 1037-1049.
- 7 77. Vineetha, V. P.; Raghu, K. G., An Overview on Arsenic Trioxide-Induced  
8 Cardiotoxicity. *Cardiovascular Toxicology* **2019**, *19* (2), 105-119.
- 9 78. Bommarito, P. A.; Beck, R.; Douillet, C.; Del Razo, L. M.; Garcia-Vargas, G.-G.;  
10 Valenzuela, O. L.; Sanchez-Peña, L. C.; Styblo, M.; Fry, R. C., Evaluation of plasma  
11 arsenicals as potential biomarkers of exposure to inorganic arsenic. *Journal of Exposure*  
12 *Science & Environmental Epidemiology* **2019**, *29* (5), 718-729.
- 13 79. Popowich, A.; Zhang, Q.; Le, X. C., Arsenobetaine: the ongoing mystery. *National*  
14 *Science Review* **2016**, *3* (4), 451-458.
- 15 80. Román, D.; Pizarro, I.; Rivera, L.; Cámara, C.; Palacios, M.; Gómez, M.; Solar, C.,  
16 An approach to the arsenic status in cardiovascular tissues of patients with coronary heart  
17 disease. *Human & Experimental Toxicology* **2011**, *30* (9), 1150-1164.  
18  
19

1 **Table 1.** Baseline characteristics of the study populations.

<b>Characteristic</b>	<b>AMI (n=101)</b>	<b>Control (n=66)</b>	<b>p-value<sup>a</sup></b>
<b><i>Demographic variables</i></b>			
Age (Median [Min-Max])	57 (33 - 81)	54.5 (40 - 71)	2.66E-01
Gender (Female) (%)	12.9	40.9	<u>6.30E-04</u>
Smoker (%)			
Non	37.6	90.9	
Current	35.6	3.0	
Ex	26.7	6.1	
Race (%)			<u>1.00E-14</u>
Chinese	27.7	60.6	
Malay	21.8	9.1	
Indian	6.9	30.3	
Others	43.6	0.0	
<b><i>Cardiovascular risk factors based on medical history</i></b>			
Prior MI (%)	4.0	0.0	1.54E-01
FH of CHD (%)	20.8	10.6	9.40E-02
Diabetes (%)	20.8	12.1	2.10E-01
Hypertension (%)	43.6	28.8	7.20E-02
Dyslipidemia (%)	42.6	77.3	<u>3.30E-05</u>
<b><i>Other cardiovascular risk factors, predictors of AMI and adverse events (Median [Min-Max])</i></b>			
DBP, mm Hg	83.50 (39 - 138)	74 (53 - 107)	<u>1.65E-04</u>
SBP, mm Hg	140 (74 - 241)	127 (97 - 175)	<u>8.22E-06</u>
Triglyceride, mmol/L	1.50 (0.35 - 5.58)	1.38 (0.37 - 4.37)	5.12E-01
Cholesterol, mmol/L	5.01 (3.20 - 7.40)	5.32 (4.05 - 7.37)	<u>1.51E-03</u>
HDL-C, mmol/L	1.03 (0.67 - 9.40)	1.34 (0.80 - 2.31)	<u>6.64E-10</u>
LDL-C, mmol/L	3.20 (1.60 - 5.51)	3.27 (2.19 - 5.25)	1.07E-01
WBC, × 10 <sup>9</sup> /L	10.85 (4.40 - 25.90)	5.50 (2.60 - 9.0)	<u>1.46E-20</u>
Platelet, × 10 <sup>9</sup> /L	250.5 (134 - 649)	258 (165 - 599)	3.79E-01
Creatinine, mmol/L	88.5 (51 - 142)	69 (42 - 97)	<u>3.90E-13</u>

hsTnT, pg/mL	1726 (62 - 9819)	6 (3 - 18)	<u>8.83E-28</u>
NTproBNP, pg/mL	718 (68 - 6819)	36 (7 - 150)	<u>3.01E-27</u>

---

- 1 <sup>a</sup> Significant *p*-values are underlined.
- 2 Abbreviations used in the table: FH, family history; DBP, diastolic blood pressure; SBP, systolic blood
- 3 pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
- 4 WBC, white blood cells; hsTnT, high-sensitivity troponin T; NTproBNP, N-terminal-pro hormone
- 5 brain natriuretic peptides.

1 **Table 2.** Independent determinants of each metallomic feature among study participants based  
 2 on backwards elimination linear regression.

Metallomic feature	Independent determinant(s) <sup>a</sup>	$\beta^b$	Standard error	Level of significance <sup>c</sup>
<i>Essential elements</i>				
Ca, $\mu\text{g/mL}$	nil			
Co, $\text{ng/mL}$	nil			
Cu, $\mu\text{g/mL}$	Gender (Female)	0.15	0.04	**
	Cholesterol	-0.12	0.04	**
	LDL-C	0.14	0.05	**
Fe, $\mu\text{g/mL}$	nil			
K, $\mu\text{g/mL}$	nil			
Mg, $\mu\text{g/mL}$	Race (Indian)	-4.92	2.42	*
	Smoker (Current)	11.85	2.16	****
Mn, $\text{ng/mL}$	Race (Chinese)	-6.29	1.99	**
Na, $\text{mg/mL}$	nil			
P, $\mu\text{g/mL}$	nil			
S, $\mu\text{g/mL}$	nil			
Se, $\text{ng/mL}$	Race (Chinese)	23.84	3.91	****
	Race (Malay)	17.12	4.92	***
Zn, $\mu\text{g/mL}$	Race (Chinese)	-10.82	3.19	***
	Race (Indian)	-12.32	3.93	**
	Smoker (Current)	13.98	3.00	****
<i>Non-essential or toxic elements</i>				
Al, $\text{ng/mL}$	Smoker (Current)	685.80	214.09	**
As, $\text{ng/mL}$	White blood cell	-0.14	0.048	**
Ba, $\text{ng/mL}$	Race (Indian)	120.94	41.96	**
	White blood cell	11.50	3.89	**
Cd, $\text{ng/mL}$	Smoker (Current)	0.25	0.06	****
Cr, $\text{ng/mL}$	Race (Indian)	91.35	30.08	**
Ni, $\text{ng/mL}$	nil			
Rb, $\text{ng/mL}$	Smoker (Current)	33.59	11.40	**
Sr, $\text{ng/mL}$	Smoker (Current)	29.27	5.24	****
U, $\text{ng/mL}$	Smoker (Current)	0.51	0.11	****
V, $\text{ng/mL}$	Smoker (Current)	2.10	0.50	****
<i>Element product or ratios</i>				
Ca/Mg	Smoker (Current)	-0.035	0.011	**
	Cholesterol	0.038	0.012	**
	LDL-C	-0.032	0.013	*
Ca $\times$ P, $\times 10^{-2}$	Smoker (Current)	0.977	0.361	**
	Cholesterol	-0.446	0.163	**
	Triglyceride	-0.339	0.171	*



Cu/Se	Race (Chinese)	-4.100	0.551	****
	Race (Malay)	-2.808	0.689	****
	Gender (Female)	1.604	0.534	**
	Cholesterol	-1.298	0.566	*
	LDL-C	1.553	0.613	*
Cu/Zn	Creatinine	0.003	0.001	*
Fe/Cu	nil			
P/Mg	nil			
Na/K	nil			
Zn/Se	Smoker (Current)	127.49	26.98	****

1 <sup>a</sup> Variables presented here are the significant variables ( $\alpha = 0.01$ ) after backwards elimination of model  
 2 fitted with age, gender, smoking status, race, dyslipidemia, triglyceride, cholesterol, HDL-C, LDL-C,  
 3 white blood cell, platelet, and creatinine as independent variables.

4 <sup>b</sup> Difference in mean levels of the respective element or element ratio/product associated with a 1-unit  
 5 increase in the independent variable. Units for each variable can be found in Table 1.

6 <sup>c</sup> Level of significance: \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ ; \*\*\*,  $p \leq 0.001$ ; \*\*\*\*,  $p \leq 0.0001$ .

7

1 **Table 3.** Descriptive statistics and statistical comparisons between metallomic profiles of AMI  
 2 patients at T1 versus healthy controls.

Metallomic feature	Independent determinants	AMI (n=101; Median [IQR])	Control (n=66; Median [IQR])	↑ or ↓ in AMI	p-value <sup>a</sup>	Adjusted level of significance <sup>b</sup>
<i>Essential elements</i>						
Ca, µg/mL	nil	6.41 (5.74 - 7.19)	6.27 (5.74 - 6.74)	-	3.10E-01	N.A.
Co, ng/mL	nil	1.05 (0.64 - 1.48)	1.14 (0.90 - 1.80)	-	1.58E-01	N.A.
Cu, µg/mL	Gender, cholesterol, LDL-C	0.85 (0.72 - 1.01)	0.73 (0.65 - 0.85)	↑	1.20E-03 **	**
Fe, µg/mL	nil	0.95 (0.70 - 1.27)	1.17 (0.94 - 1.42)	↓	2.18E-03 **	N.A.
K, µg/mL	nil	159.67 (131.46 - 209.03)	148.96 (127.67 - 189.56)	-	3.01E-01	N.A.
Mg, µg/mL	Race, smoking status	24.77 (21.26 - 29.07)	22.92 (21.14 - 25.23)	↑	1.82E-02 *	-
Mn, ng/mL	Race, smoking status	12.49 (6.15 - 18.37)	14.02 (10.40 - 18.77)	-	1.84E-01	-
Na, mg/mL	nil	4.16 (3.72 - 4.58)	3.82 (3.49 - 4.22)	↑	2.02E-02 *	N.A.
P, µg/mL	nil	91.38 (77.97 - 101.49)	96.26 (87.18 - 107.94)	↓	3.11E-02 *	N.A.
S, µg/mL	nil	807.66 (732.68 - 912.45)	833.95 (766.46 - 900.54)	-	6.14E-01	N.A.
Se, ng/mL	Race	90.31 (74.97 - 106.68)	99.98 (87.90 - 111.34)	↓	5.42E-03 **	**
Zn, µg/mL	Race, smoking status	1.50 (1.24 - 1.71)	1.53 (1.41 - 1.73)	-	2.29E-01	-
<i>Non-essential or toxic elements</i>						
Al, ng/mL	Smoking status	937.32 (689.16 - 128.27)	822.51 (648.36 - 946.56)	↑	1.16E-02 *	-
As, ng/mL	White blood cells	1.32 (0.80 - 2.31)	2.12 (1.41 - 3.76)	↓	6.07E-05 ****	***
Ba, ng/mL	Race, white blood cells	25.15 (15.73 - 35.61)	19.88 (15.19 - 24.26)	↑	1.41E-03 **	*
Cd, ng/mL	Smoking status	0.16 (0.00 - 0.34)	0.16 (0.0 - 0.28)	-	6.15E-01	-
Cr, ng/mL	Race	61.64 (52.37 - 75.44)	66.75 (49.13 - 80.10)	-	5.23E-01	-

Ni, ng/mL	nil	0.97 (0.97 - 63.40)	16.21 (0.97 - 66.51)	-	8.30E-01	N.A.
Rb, ng/mL	Smoking status	171.96 (147.87 - 211.63)	152.36 (135.44 - 184.01)	↑	2.70E-03 **	-
Sr, ng/mL	Smoking status	49.79 (39.82 - 61.48)	44.47 (39.22 - 51.07)	↑	3.38E-02 *	-
U, ng/mL	Smoking status	0.19 (0.04 - 0.33)	0.18 (0.00 - 0.33)	-	5.35E-01	-
V, ng/mL	Smoking status	1.13 (0.57 - 1.56)	0.98 (0.57 - 1.43)	-	3.89E-01	-

**Element product or ratios**

Ca/Mg	Smoking status, cholesterol, LDL-C	0.26 (0.22 - 0.30)	0.27 (0.25 - 0.30)	-	7.53E-02	-
Ca×P, × 10 <sup>2</sup>	Smoking status, cholesterol, triglycerides	5.76 (4.65 - 7.32)	6.25 (5.22 - 7.26)	↓	2.53E-03 **	-
Cu/Se	Race, gender, cholesterol, LDL-C	9.77 (7.77 - 11.51)	7.36 (6.38 - 8.56)	↑	6.08E-07 ****	****
Cu/Zn	Creatinine	0.56 (0.43 - 0.72)	0.48 (0.42 - 0.56)	↑	9.68E-03 **	*
Fe/Cu	nil	1.16 (0.79 - 1.54)	1.57 (1.17 - 1.95)	↓	1.81E-05 ****	N.A.
P/Mg	nil	3.63 (3.09 - 4.54)	4.14 (3.81 - 4.86)	↓	5.24E-04 ***	N.A.
Na/K	nil	25.67 (22.18 - 28.66)	25.16 (22.46 - 28.30)	-	7.95E-01	N.A.
Zn/Se	Smoker status	17.13 (13.22 - 23.08)	15.48 (13.38 - 18.46)	-	1.57E-01	-

1 <sup>a</sup> *p*-values were derived from *p*-values obtained by Mann Whitney test for difference between AMI and  
2 healthy groups.

3 <sup>b</sup> *p*-values obtained via ANCOVA for difference between AMI and healthy groups, with the independent  
4 determinants set as covariates.

5 Levels of significance shown: -, *p* ≥ 0.05; \*, *p* ≤ 0.05; \*\*, *p* ≤ 0.01; \*\*\*, *p* ≤ 0.001; \*\*\*\*, *p* ≤ 0.0001.

6

1 **Table 4.** Descriptive statistics and repeated measures ANOVA assessing changes in significant  
2 metallomic features across 3 time-points.

Metallomic feature	AMI <sup>a</sup> (n=101; Median [IQR])			p-value	Kendall's W <sup>c</sup>	Pairwise comparisons <sup>d</sup>
	T1	T2	T3			
<b>Essential elements (Median [IQR])</b>						
Cu, µg/mL	0.85 (0.72 - 1.01)	0.87 (0.75 - 0.95)	0.77 (0.68 - 0.86)	6.89E-05 ****	0.10 (small)	-   ****
Fe, µg/mL	0.95 (0.70 - 1.27)	1.01 (0.85 - 1.21)	0.93 (0.75 - 1.13)	1.51E-01	N.A.	N.A.
Na, mg/mL	4.16 (3.72 - 4.58)	4.12 (3.55 - 4.55)	4.03 (3.69 - 4.55)	9.66E-01	N.A.	N.A.
P, µg/mL	91.38 (77.97 - 101.49)	83.34 (69.86 - 100.19)	85.52 (73.74 - 100.82)	3.80E-01	N.A.	N.A.
Se, ng/mL	90.31 (74.97 - 106.68)	94.11 (78.83 - 109.04)	94.50 (73.98 - 107.52)	1.91E-02 *	0.04 (small)	**   -
<b>Non-essential or toxic elements (Median [IQR])</b>						
As, ng/mL	1.32 (0.80 - 2.31)	2.00 (1.34 - 3.58)	1.99 (0.85 - 3.66)	4.24E-06 ****	0.13 (small)	****   -
Ba, ng/mL	25.15 (15.73 - 35.61)	21.84 (15.82 - 30.31)	19.52 (12.17 - 28.25)	6.97E-02	N.A.	N.A.
<b>Element product or ratios (Median [IQR])</b>						
Cu/Zn	0.56 (0.43 - 0.72)	0.58 (0.46 - 0.70)	0.54 (0.43 - 0.65)	3.88E-01	N.A.	N.A.
P/Mg	3.63 (3.09 - 4.54)	3.63 (2.93 - 4.75)	4.09 (3.44 - 5.07)	2.70E-03 **	0.06	-   **
Cu/Se	9.77 (7.77 - 11.51)	9.14 (7.54 - 11.18)	8.20 (7.06 - 8.81)	1.64E-06 ****	0.14	*   ***
Fe/Cu	1.16 (0.79 - 1.54)	1.21 (1.00 - 1.46)	1.22 (0.99 - 1.47)	4.88E-01	N.A.	N.A.
<b>Positive cardiac marker</b>						
hsTnT, pg/mL	1726 (62 - 9819)	13 (8 - 19)	9 (7 - 14)	3.28E-09 ****	0.81 (large)	****   ****


3 <sup>a</sup> T1, 24-48 hours post-PCI; T2, follow-up at 1 month after T1; T3: follow-up at 6 months after T1.

4 <sup>b</sup> Levels of significance and p-values were derived from the Friedman test. -,  $p \geq 0.05$ ; \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ ; \*\*\*,  $p \leq 0.001$ ; \*\*\*\*,  $p \leq 0.0001$ .

5 <sup>c</sup> Kendall's coefficient of concordance (W) was used as a measure of the Friedman test's effect size.  
6 Kendall's W uses the Cohen's interpretation guidelines of:  $W < 0.3$ , small effect;  $W < 0.5$ , moderate  
7 effect;  $W \geq 0.5$ , large effect. Confidence intervals are calculated by bootstrap.


8 <sup>d</sup> Post-hoc pairwise comparisons were done using paired Wilcoxon signed-rank test with Bonferroni  
9 adjustment. Level of significance given on the left is derived from comparison between T1 and T2,  
10 while the one on the right is from T2 and T3's comparison.  
11

12




1

2 **Figure 1.** Heatmap showing the correlation between metallic features (\*,  $p \leq 0.05$ ; \*\*,  $p \leq$   
 3  $0.01$ , \*\*\*,  $p \leq 0.001$ ; \*\*\*\*,  $p \leq 0.0001$ ).



1

2 **Figure 2.** Violin plots showing trajectories of metallomic features with significance changes  
3 and hsTnT across 3 time-points (T1, 24-48 hours after PCI; T2, 1 month after T1; T3, 6 months  
4 after T1).



1

2 **Figure 3.** Classification performance of random forest models built with metallomic features  
 3 and traditional cardiovascular risk factors as shown by (A) ROC curves and most important  
 4 variables identified in the model, and (B) predictive accuracies.